SAB Biotherapeutics, Inc. (SABS)

NCM – Real Time Price. Currency in USD

3.80

-0.07 (-1.81%)

At close: Jun 26, 2026, 4:00 PM EDT

3.81

+0.01 (0.34%)

After-hours: Jun 26, 2026, 7:14 PM EDT

29.05.2026

SAB BIO to Present Data on SAB-142 at The American Diabetes Association's 2026 Scientific Sessions and FOCIS 2026 Annual Meeting

Data will highlight deeper mechanistic insights and long-term dosing potential of SAB-142, a fully human multi-specific ATG for newly diagnosed Stage 3 T1D Data will highlight deeper mechanistic insights and long-term dosing potential of SAB-142, a fully human multi-specific ATG for newly diagnosed Stage 3 T1D

12.05.2026

SAB Biotherapeutics Q1 Earnings Call Highlights

SAB Biotherapeutics NASDAQ: SABS said its lead type 1 diabetes candidate, SAB-142, remains on track in a registrational Phase 2b trial, as the clinical-stage biopharmaceutical company reported a wider first-quarter loss alongside higher research and development spending.

12.05.2026

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027

05.05.2026

SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET

MIAMI, May 05, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that its first quarter 2026 financial results will be issued in the morning of Tuesday, May 12, 2026. Management will host a conference call and webcast at 8:30 AM ET to discuss the results and provide business updates.

22.04.2026

SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026

All 4 T1D participants receiving SAB-142 showed C-peptide preservation with 3 of the 4 participants showing a super responder profile concomitant with T cell exhaustion T1D participants receiving SAB-142 showed improved glycemic control MIAMI, April 22, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today presented additional clinical and mechanistic data from the Phase 1 HUman anti-thymocyte biologic in first-in-MAN (HUMAN) clinical trial of SAB-142 at the 21st Immunology of Diabetes Society (IDS) Congress in Brisbane, Australia. The additional data presented for SAB-142 highlighted C-peptide preservation with a super responder profile among 3 of the 4 participants with T1D, correlated with evidence of CD4+ T conventional (Tconv) cell exhaustion.

15.04.2026

SAB Biotherapeutics Looks Undervalued If SAB-142 Delivers In Type 1 Diabetes

SAB Biotherapeutics is a clinical-stage biotech centered on SAB-142, a disease-modifying T1D candidate targeting both stage 2 and stage 3 patients. SAB-142 may preserve beta-cell function and C-peptide with a cleaner safety profile than animal-derived immune therapies, supporting potential repeat dosing. The registrational Phase 2b SAFEGUARD study is the key value driver, while broader autoimmune programs provide secondary optionality.

19.03.2026

SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

MIAMI, March 19, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced the closing of an underwritten public offering of 19,324,677 shares of its common stock at a public offering price of $3.85 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 2,753,246 shares of common stock at a public offering price of $3.8499 per pre-funded warrant, which represents the per share public offering price less the $0.0001 per share exercise price for each pre-funded warrant. Gross proceeds from the offering were approximately $85 million, before deducting underwriting discounts and commissions and offering expenses. SAB BIO has granted the underwriters a 30-day option to purchase up to an additional 3,311,688 shares of common stock on the same terms and conditions. All of the securities sold in the offering were offered by SAB BIO.

Videos

No Data

There is no data to display

Press releases

12.05.2026

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027

22.04.2026

SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026

19.03.2026

SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

18.03.2026

SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

MIAMI, March 17, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced the pricing of an underwritten public offering of 19,324,677 shares of its common stock at a public offering price of $3.85 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 2,753,246 shares of common stock at a public offering price of $3.8499 per pre-funded warrant, which represents the per share public offering price less the $0.0001 per share exercise price for each pre-funded warrant. Gross proceeds from the offering are expected to be approximately $85 million, before deducting underwriting discounts and commissions and offering expenses. SAB BIO has granted the underwriters a 30-day option to purchase up to an additional 3,311,688 shares of common stock on the same terms and conditions. All of the securities in the offering are to be sold by SAB BIO. The offering is expected to close on or about March 19, 2026, subject to the satisfaction of customary closing conditions.

SAB Biotherapeutics, Inc. (SABS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

SAB Biotherapeutics, Inc. (SABS)

SAB BIO to Present Data on SAB-142 at The American Diabetes Association's 2026 Scientific Sessions and FOCIS 2026 Annual Meeting

SAB Biotherapeutics Q1 Earnings Call Highlights

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET

SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026

SAB Biotherapeutics Looks Undervalued If SAB-142 Delivers In Type 1 Diabetes

SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

Videos

No Data

Press releases

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026

SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

SAB BIO to Present Data on SAB-142 at The American Diabetes Association's 2026 Scientific Sessions and FOCIS 2026 Annual Meeting

SAB Biotherapeutics Q1 Earnings Call Highlights

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET

SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026

SAB Biotherapeutics Looks Undervalued If SAB-142 Delivers In Type 1 Diabetes

SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

Videos

No Data

Press releases

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026

SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

Search stocks

SAB Biotherapeutics, Inc. (SABS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

SAB Biotherapeutics, Inc. (SABS)

SAB BIO to Present Data on SAB-142 at The American Diabetes Association's 2026 Scientific Sessions and FOCIS 2026 Annual Meeting

SAB Biotherapeutics Q1 Earnings Call Highlights

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET

SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026

SAB Biotherapeutics Looks Undervalued If SAB-142 Delivers In Type 1 Diabetes

SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

Videos

No Data

Press releases

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026

SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

SAB BIO to Present Data on SAB-142 at The American Diabetes Association's 2026 Scientific Sessions and FOCIS 2026 Annual Meeting

SAB Biotherapeutics Q1 Earnings Call Highlights

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET

SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026

SAB Biotherapeutics Looks Undervalued If SAB-142 Delivers In Type 1 Diabetes

SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

Videos

No Data

Press releases

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026

SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants